Nicotinamide riboside supplementation to improve stem cell transplant outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot feasibility study investigates the safety and tolerability of nicotinamide riboside (NR) supplementation in patients undergoing allogeneic hematopoietic cell transplantation (HCT). The study aims to determine if increasing NAD+ levels through NR can enhance engraftment, which is the process where transplanted stem cells grow in the bone marrow and produce new blood cells. By potentially shortening the time to engraftment, the study seeks to reduce the risks associated with prolonged recovery periods, such as the need for transfusions and antibiotics. Participants will receive NR supplementation and be monitored for neutrophil and platelet recovery post-transplant.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
* Subject must meet program eligibility criteria\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
* HLA-identical related donor or unrelated human donor source with bone marrow graft.
* Subjects must provide a written informed consent.

Exclusion Criteria:

* History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
* Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
* Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

Where it's running

• Cleveland Clinic, Case Comprehensive Cancer Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Ronald Sobecks, MD — Cleveland Clinic, Case Comprehensive Cancer Center
• Study coordinator: Ronald Sobecks, MD
• Email: TaussigResearch@ccf.org
• Phone: 1-866-223-8100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjusting Alemtuzumab Dosing for Bone Marrow Transplantation

  This study is testing if adjusting the dose of alemtuzumab can help kids and young adults getting a bone marrow transplant have fewer complications and recover better.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT05501756

• Long-term心理 and cognitive check after stem cell transplant for immune deficiencies

  This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07766304

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

• Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant

  This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.

  Recruiting at 18 sites Phase 3 First Affiliated Hospital of Zhejiang University · Fuzhou, Fujian and 17 other locations · NCT07396480

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.